tag:blogger.com,1999:blog-36768584.post8964661916109323098..comments2024-03-03T18:49:34.382-05:00Comments on Omics! Omics!: Can ONT Maintain Grip on Burgeoning Flowcell Herd?Keith Robisonhttp://www.blogger.com/profile/04765318239070312590noreply@blogger.comBlogger4125tag:blogger.com,1999:blog-36768584.post-36461619872759720492020-02-10T18:27:01.180-05:002020-02-10T18:27:01.180-05:00Sequel II versus ONT (pick one of the many platfor...Sequel II versus ONT (pick one of the many platforms)? Seems like there are some glaring issues still, but who knows, it may be enough to displace an expensive piece of capital with Sequel II?Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-36768584.post-53397659433463726582020-02-06T01:02:23.710-05:002020-02-06T01:02:23.710-05:00No. i dont think ONT will be in the clinic any tim...No. i dont think ONT will be in the clinic any time soon. I don't see them replacing short read sequencers for the majority of applications ever. Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-36768584.post-54247672445105721372020-02-01T10:13:27.561-05:002020-02-01T10:13:27.561-05:00Why? ONT is one of the most interesting topics rig...Why? ONT is one of the most interesting topics right now?<br /><br />Do you think ONT will break into the clinic and challenge Illumina in the next years? For example in oncology are a lot of targeted drugs available now and more coming but the testing takes a lot of time and I'm not sure how good the tests are at detecting fusions and amplifications for stuff like ALK, NTREK, RET, ROS1Tomhttps://www.blogger.com/profile/00524624798533699020noreply@blogger.comtag:blogger.com,1999:blog-36768584.post-50680229971261912642020-02-01T03:25:02.001-05:002020-02-01T03:25:02.001-05:00You’ve really got it in for ONT these days haven’t...You’ve really got it in for ONT these days haven’t you. Surely theres other stuff in the genomics space to blog about.Anonymousnoreply@blogger.com